Investors

Media Coverage

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Media Coverage

Enveric Hires Fish & Richardson To Defend IP Against Petition Claiming Its Patent Contains Claims Relevant To AbbVie’s $1.2B Bretisilocin Acquisition [Benzinga]

October 15, 2025

AbbVie Could Face Patent Battle Over Depression Asset Gained in Gilgamesh Deal [SeekingAlpha]

October 15, 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch [Microdose]

October 15, 2025

Enveric Biosciences Hires Fish & Richardson to Defend Patent Tied to AbbVie Deal [Investing.com]

October 15, 2025

After the Billion-Dollar Psychedelic Bet: Who’s Next for Big Pharma? [Microdose]

October 10, 2025

How Enveric Biosciences Is Prepping For Its First IND [Clinical Leader]

October 10, 2025

The Next Chapter in Psychedelic Medicine: How Enveric Biosciences Stands Apart [HoneySuckle]

September 22, 2025

With big pharma circling psychedelics, the next breakthrough may not come from tripping at all [Microdose]

September 16, 2025

AbbVie’s $1B Psychedelic Bet: Who’s Next in the Neuroplastogen Gold Rush? [Microdose]

August 28, 2025

Reimagining Psychedelics: Mental Wellness Without the Roadblocks [Pharmaceutical Online]

August 19, 2025

1
2
3
…
14
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2025 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.